Phase 1 trial of first-in-class anti-CD96 monoclonal antibody inhibitor, GSK6097608, monotherapy and combination with anti–PD-1 monoclonal antibody, dostarlimab, in advanced solid tumors

Jemperli (dostarlimab) - GSK

GSK6097608 - GSK

https://jitc.bmj.com//content/9/Suppl_2/A518

Omid Hamid 1; Dawn Baxter 2; Rachael Easton 2; Lilian Siu 3

Oct 1, 2021